IP Verse

Cns Delivery Of Therapeutic Agents

EP3103469

SHIRE HUMAN GENETIC THERAPIES, INC.
Application Number
EP16179150A
Filing Date
Jun 25, 2011
Status
Granted And Under Opposition
Nov 6, 2020
Grant Date
Dec 9, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3103469B1 was granted on Dec 9, 2020 by Shire Human Genetic Therapies, Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GREEN CROSS CORPORATIONSep 9, 2021 N.A.

More Opposed Patents of Shire Human Genetic Therapies, Inc.

The table below shows the patents of Shire Human Genetic Therapies, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2858679Pulmonary Delivery Of Mrna To Non-Lung Target CellsJun 5, 20241
EP3626258Methods And Compositions For Cns Delivery Of Iduronate-2-SulfataseAug 4, 20211
EP2970456Methods And Compositions For Delivering Mrna Coded AntibodiesMay 19, 20214

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents